Positive impact.  Merck's earnings call highlighted strong data from the luspatercept Phase 2 trials, with accelerated patient enrollment and promising results.  Management's confidence in the program, combined with anticipated top-line results from Phase 3 trials in the mid-2018 timeframe, suggests significant potential for the stock price in the short term. 
[1]
